Glaucoma drug developer Aerie Pharmaceuticals has closed on $15 million in financing, according to securities filings.

The privately-held New Jersey company, which operates its R&D labs in Research Triangle Park, set out last December to raise that $15 million. The company’s latest securities filings show it has reached that amount and now aims to boost that total to $18 million.

The financing is a combination of debt, equity and options to acquire other securities. A total of five unnamed investors participated in the financing. Investors in Aerie include Clarus Ventures and Sofinova Ventures, who led a $30 million series B round in 2011. Other investors include Osage University Partners, Alta Partners and TPG Biotech.

Aerie has two clinical-stage compounds focused on glaucoma. The company’s lead candidate, a “dual-action” product, has completed phase II clinical trials and is ready to start phase III studies. A second candidate approaches glaucoma with a “triple action” mechanism. That compound is moving toward phase II studies. The company’s technology is based on research originally developed at Duke University.

Aerie is now led by a new CEO. Dr. Vicente Anido, who was chairman of Aerie’s board of directors, took over as CEO in July from Dr. Thomas van Haarlem, who was the founding CEO of the company. Van Haarlem resigned his seat on Aerie’s board but remained as a consultant. He is also president of Novaer Holdings, which is the owner of ophthalmic technologies developed at Aerie.